Literature DB >> 11028685

Angiotensin AT1 receptor over-expression in hypercholesterolaemia.

K Strehlow1, S Wassmann, M Böhm, G Nickenig.   

Abstract

Angiotensin II mediates most of the biological effects of the renin-angiotensin system (RAS), such as vasoconstriction and cell proliferation, via stimulation of the angiotensin II type 1 (AT1) receptor. The AT1 receptor plays a central role in the pathogenesis of atherosclerosis and hypertension. In parallel, hypercholesterolaemia is a major risk factor for the development and progression of cardiovascular diseases. The underlying molecular events, however, are understood only partially. An important mechanism may be the interaction between hypercholesterolaemia and AT1 receptor expression in vascular tissue. Low-density lipoprotein (LDL) cholesterol leads to a profound increase in AT1 receptor expression in cultured vascular smooth muscle cells as well as in hypercholesterolaemic rabbits. This up-regulation is associated with an enhanced functional response upon stimulation with angiotensin II. Over-expression of the vascular AT1 receptor can also be observed in hypercholesterolaemic men and is prevented by treatment with 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors. These findings may explain why hypercholesterolaemia is frequently associated with hypertension and why blockade of the RAS attenuates the progression of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11028685     DOI: 10.3109/07853890008995944

Source DB:  PubMed          Journal:  Ann Med        ISSN: 0785-3890            Impact factor:   4.709


  22 in total

1.  Associations of ApoAI and ApoB-containing lipoproteins with AngII-induced abdominal aortic aneurysms in mice.

Authors:  Jing Liu; Hong Lu; Deborah A Howatt; Anju Balakrishnan; Jessica J Moorleghen; Mary Sorci-Thomas; Lisa A Cassis; Alan Daugherty
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-06-04       Impact factor: 8.311

Review 2.  Hypertension and lipids: lipid factors in the hypertension syndrome.

Authors:  Gary E Sander; Thomas D Giles
Journal:  Curr Hypertens Rep       Date:  2002-12       Impact factor: 5.369

3.  Future direction of renal positron emission tomography.

Authors:  Zsolt Szabo; Jinsong Xia; William B Mathews; Phillip R Brown
Journal:  Semin Nucl Med       Date:  2006-01       Impact factor: 4.446

4.  Effect of repeatedly heated palm olein on blood pressure-regulating enzymes activity and lipid peroxidation in rats.

Authors:  Xin-Fang Leong; Jumat Salimon; Mohd Rais Mustafa; Kamsiah Jaarin
Journal:  Malays J Med Sci       Date:  2012-01

5.  Prevalence of tinnitus in patients withhypertension and the impact of different anti hypertensive drugs on the incidence of tinnitus: A prospective, single-blind, observational study.

Authors:  Claudio Borghi; Cristina Brandolini; Maria Grazia Prandin; Ada Dormi; Giovanni Carlo Modugno; Antonio Pirodda
Journal:  Curr Ther Res Clin Exp       Date:  2005-09

Review 6.  Factors Responsible for Obesity-Related Hypertension.

Authors:  Kyungjoon Lim; Kristy L Jackson; Yusuke Sata; Geoffrey A Head
Journal:  Curr Hypertens Rep       Date:  2017-07       Impact factor: 5.369

Review 7.  The renin angiotensin system as a risk factor for coronary artery disease.

Authors:  J A Farmer; G Torre-Amione
Journal:  Curr Atheroscler Rep       Date:  2001-03       Impact factor: 5.113

Review 8.  The role of statin therapy in the management of cardiomyopathies.

Authors:  Kumudha Ramasubbu; John A Farmer
Journal:  Curr Atheroscler Rep       Date:  2009-03       Impact factor: 5.113

9.  Pathogenesis of atherosclerosis: A multifactorial process.

Authors:  Raja B Singh; Sushma A Mengi; Yan-Jun Xu; Amarjit S Arneja; Naranjan S Dhalla
Journal:  Exp Clin Cardiol       Date:  2002

10.  Angiotensin II AT1 receptor blockade normalizes CD11b+ monocyte production in bone marrow of hypercholesterolemic monkeys.

Authors:  William B Strawn; Carlos M Ferrario
Journal:  Atherosclerosis       Date:  2007-08-09       Impact factor: 5.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.